MAIA Biotechnology Inc Dossier
Qualitative Analysis
Business overview
MAIA Biotechnology, Inc. (Nasdaq: MAIA) is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted immunotherapies for cancer. The company's lead asset is ateganosine (also known as THIO, 6-thio-dG, or 6-thio-2'-deoxyguanosine), a first-in-class investigational dual-mechanism drug candidate that incorporates telomere targeting and immunogenicity. THIO is designed to induce telomerase-dependent telomeric DNA modification, selective cancer cell death, and robust immune responses. MAIA's primary clinical focus is on treating telomerase-positive cancers, particularly non-small cell lung cancer (NSCLC).
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing the clinical development of lead candidate ateganosine (THIO), the first and only clinical-stage telomere-targeting agent, through the concurrent Phase 2 THIO-101 expansion and pivotal Phase 3 THIO-104 trials for advanced NSCLC.
Expected impact: Establish a breakthrough therapeutic option in the $50+ billion global immunotherapy market for hard-to-treat, telomerase-positive cancers.
Developing in-house second-generation telomere-targeting small molecules designed to exhibit enhanced efficacy compared to first-generation ateganosine.
Expected impact: Broaden the company's oncology platform and secure long-term pipeline sustainability.
Expanding the clinical footprint of the Phase 2 THIO-101 trial into the United States following FDA clearance of an updated IND application.
Expected impact: Accelerate patient recruitment and gather diverse clinical data to support FDA regulatory submissions.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Provides Libtayo (cemiplimab) at no cost for sequential administration with ateganosine in the Phase 2 THIO-101 trial, including its expanded arms.
Terms: Regeneron supplies Libtayo at no cost, representing a significant clinical trial cost savings equivalent to a $32 million non-dilutive participation.
Enables future clinical studies evaluating the combination of ateganosine sequenced with Roche's checkpoint inhibitor, Tecentriq (atezolizumab), across multiple hard-to-treat cancers.
Terms: Roche provides atezolizumab for the combination trials.
Facilitates combination trials of ateganosine sequenced with tislelizumab (Tevimbra) across multiple cancer indications, including hepatocellular carcinoma (HCC), small cell lung cancer (SCLC), and colorectal cancer (CRC).
Terms: BeOne Medicines provides tislelizumab for the trials, while MAIA sponsors and funds the clinical operations.